|
|
|
|
SJHG04 Protocol / Clinical Study
Jude News Donate Now Contact Us Shop En Espanol Patients & Parents Clinical Science Basic Science Referring MDs Careers International Volunteers Ways to Help Brain Tumors Supportive Brain Tumor Studies - Home - Clinical Science Home - Protocols - Brain Tumors - Related Topics - Protocol SJHG04 Protocol / Clinical Study A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarcevaa&...
author: St. Jude Children's Research Hospital
|
|
|
St. Jude Children's Research Hospital - Copyright 2003
SJHG04 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva™; Erlotinib Hydrochloride; OSI-774) during and after Radiotherapy in the Treatment of Patients with Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma For: Intracranial high-grade glioma and unfavorable low-grade glioma SJMB03 Treatment of Patients with Newly Diagnosed...
author: St. Jude Children's Research Hospital
|
|
|
St. Jude Children's Research Hospital - Copyright 2003
SJHG04 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva™; Erlotinib Hydrochloride; OSI-774) during and after Radiotherapy in the Treatment of Patients with Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma For: Intracranial high-grade glioma and unfavorable low-grade glioma SJMB03 Treatment of Patients with Newly Diagnosed...
author: St. Jude Children's Research Hospital
|
|
|
Brain Tumor Protocols / Clinical Studies
In order for our site to display correctly you will need a newer version of your web browser.
Opera v7 or higher (Windows, Linux) Apple's Safari (Mac OS X) Konqueror (Linux KDE Desktop) Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh) Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of...
author: St. Jude Children's Research Hospital
|
|
|
Brain Tumor Protocols / Clinical Studies
SJHG04 A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva™; Erlotinib Hydrochloride; OSI-774) during and after Radiotherapy in the Treatment of Patients with Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma For: Intracranial high-grade glioma and unfavorable low-grade glioma SJMB03 Treatment of Patients with Newly Diagnosed...
author: St. Jude Children's Research Hospital
|
|
|
Database E
E - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on- link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) • Phase 2 study of PDX in patients with relapsed or refractory Non-Hodgkin’s Lymphoma or Hodgkin's disease (B-cell) • Phase 1/2a study of PDX plus gemcitabine in patients with relapsed or refractory Non-Hodgkin’s Lymphoma or Hodgkin's disease - • Phase...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) • Phase 2 study of PDX in patients with relapsed or refractory Non-Hodgkin’s Lymphoma or Hodgkin's disease (B-cell) • Phase 1/2a study of PDX plus gemcitabine in patients with relapsed or refractory Non-Hodgkin’s Lymphoma or Hodgkin's disease - • Phase...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
|
|
Allos Therapeutics
Home.
Contact Us.
Site Map.
Search - --- » » »-- Clinical Trials | Trials Open for Enrollment Allos Therapeutics is currently enrolling patients in the following clinical trials.-Go to- www.clinicaltrials.gov for additional information.
PDX • Phase 2 study of PDX in patients with relapsed or refractory peripheral T-cell Lymphoma (PROPEL) •...
|
